PeproTech IFN beta Polyclonal Antibody, PeproTech®, Invitrogen™

Description

AA Sequence of recombinant protein: MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI LRNFYFINRL TGYLRN. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IFN-beta. Anti-Human IFN-beta-specific antibody was purified by affinity chromatography employing an immobilized Human IFN-beta matrix. Sandwich ELISA: To detect Human IFN-beta by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IFN-beta (500-P32BBt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human IFN-beta. Western Blot: To detect Human IFN-beta by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. When used in conjunction with compatible secondary reagents, the detection limit for Recombinant Human IFN-beta is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

Type I Interferons (IFN-alpha/beta) are produced primarily in response to viral infection by Natural IFN-producing cells (IPCs) as part of the host immune response. IFNs can also inhibit the development of tumors. IFN-beta binding results in the activation of the tyrosine kinases Jak1 and Tyk2, phosphorylation of members of the STAT family of transcription factors, and the transcription and expression of the immune response genes. More recently, several members of the toll-like receptor (TLR) family were found to stimulate the production IFN-beta. IFN-beta is currently used clinically for treatment of tumors, infections and multiple sclerosis.